Vivistim Stroke Recovery Trial Data Published in 2026

Researchers evaluated the Vivistim Paired VNS System in a study focusing on long-term recovery for stroke survivors.

Updated on Sept. 22, 2026 in Stroke

Vivistim Stroke Recovery Trial Data Published in 2026

Live Poll

Should insurance automatically cover breakthrough medical devices once they receive FDA approval?

In 2026, researchers published findings from the VNS-REHAB trial, which utilized the FDA-approved Vivistim Paired VNS System to aid stroke recovery. The study design required participants to be at least nine months post-ischemic stroke to ensure improvements were linked to the device rather than natural healing.

Why it matters

The study was specifically structured to isolate the efficacy of neuroplasticity-driven therapy from natural recovery progression. By requiring participants to be at least nine months post-stroke, researchers established a clearer baseline for how the device helps reorganize brain connections.

The pivotal trial enrolled 108 patients, with 107 completing the intensive protocol involving 90-minute sessions with at least 300 task repetitions. The study required participants to be at least nine months post-ischemic stroke at enrollment.

The players

Dawson et al.

These researchers led the publication of the pivotal trial results and subsequent subgroup analyses of the VNS-REHAB data.

Kimberley et al.

This team authored the 2026 two-year follow-up paper examining the long-term outcomes of the trial.

The details

Therapists followed a standardized upper-limb protocol, with researchers reviewing session videos to ensure consistency across sites. The Vivistim system is designed to be paired with this repetitive therapy to actively drive neuroplasticity and reorganize neural connections.

2019: Initial paired VNS rehabilitation study published.
2021: Pivotal trial results published by Dawson et al.
2023: Subgroup analysis published by Dawson.
2026: Two-year follow-up paper published by Kimberley et al.

The Big Picture

This research builds upon the foundation established by the GRASP Registry, which tracks commercially implanted patients to monitor real-world outcomes. The findings contribute to ongoing efforts to refine stimulation parameters for neuroplasticity.

Patients who are at least nine months post-stroke may discuss this FDA-approved therapy with their neurologists to determine if it is a suitable treatment option. The standardized protocol requires a commitment to intensive rehabilitation sessions to potentially improve motor function.

The takeaway

The success of the trial indicates that neuroplasticity-driven interventions can provide meaningful improvements even for those long past their initial injury. Patients and providers should focus on standardized, high-repetition therapy protocols to maximize potential gains from VNS systems.